Genentech Will Collaborate With CGI To Develop Oncology, Autoimmune Target
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech will pay CGI $25 mil. up front with the potential for $500 mil. in milestone payments.
You may also be interested in...
Genentech VP-Business Development Joseph McCracken: An Interview With "The Pink Sheet" DAILY (Part 2 of 2)
Partnership with Roche has been the "ultimate win/win deal," McCracken says.
Genentech VP-Business Development Joseph McCracken: An Interview With "The Pink Sheet" DAILY (Part 2 of 2)
Partnership with Roche has been the "ultimate win/win deal," McCracken says.
Genentech Gains PARP Inhibitor Through Inotek Deal
The lead product, INO-1001, is in Phase Ib for malignant melanoma.